Quince Therapeutics, Inc.QNCXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank73
3Y CAGR-38.1%
5Y CAGR-1.0%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
-38.1%/yr
vs +55.0%/yr prior
5Y CAGR
-1.0%/yr
Recent deceleration
Acceleration
-93.1pp
Decelerating
Percentile
P73
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 13.34% |
| Q2 2025 | -18.38% |
| Q1 2025 | -26.86% |
| Q4 2024 | -5.19% |
| Q3 2024 | 16.77% |
| Q2 2024 | -4.60% |
| Q1 2024 | -37.53% |
| Q4 2023 | -26.65% |
| Q3 2023 | -25.89% |
| Q2 2023 | -3.29% |
| Q1 2023 | 37.34% |
| Q4 2022 | 12.36% |
| Q3 2022 | 56.23% |
| Q2 2022 | 4.23% |
| Q1 2022 | -11.30% |
| Q4 2021 | 16.61% |
| Q3 2021 | 1.81% |
| Q2 2021 | -29.41% |
| Q1 2021 | -2.72% |
| Q4 2020 | -7.22% |
| Q3 2020 | 14.01% |
| Q2 2020 | -33.61% |
| Q1 2020 | 1.60% |
| Q4 2019 | -24.22% |
| Q3 2019 | -40.39% |
| Q2 2019 | 13.53% |
| Q1 2019 | -82.91% |
| Q4 2018 | -87.14% |
| Q3 2018 | 19.40% |
| Q2 2018 | 17.09% |
| Q1 2018 | 0.00% |